Repligen Corp. Stock
Price
Target price
€99.92
€99.92
0.850%
0.84
0.850%
€150.44
13.03.26 / Tradegate
WKN: 870980 / Symbol: RGEN / Name: Repligen Corp / Stock / Pharmaceuticals / Mid Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Repligen Corp. Stock
The Repligen Corp. stock is trending slightly upwards today, with an increase of €0.84 (0.850%) compared to yesterday's price.
With 18 Buy predictions and only 1 Sell predictions the community sentiment for the stock is positive.
With a target price of 150 € there is a hugely positive potential of 50.12% for Repligen Corp. compared to the current price of 99.92 €.
So far the community has only identified positive things for Repligen Corp. stock. The most positive votes were given for criterium "Worthwhile Investment for the next years".
Pros and Cons of Repligen Corp. in the next few years
Pros
?
C******** o* t** e**********
?
G***** c******* t* c**********
?
S********** s********
Cons
?
B****
?
W********* I********* f** t** n*** y****
?
M***** P*******
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Repligen Corp. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Repligen Corp. | 0.850% | -3.412% | -10.586% | -25.266% | -29.059% | -36.639% | -38.643% |
| Opko Health Inc. | 4.260% | 4.259% | -0.419% | -34.915% | -8.384% | -10.438% | -72.174% |
| Amicus Therapeutics Inc. | 0.810% | 0.000% | 3.333% | 54.037% | 3.333% | 16.629% | 37.778% |
| Viatris Inc. | -1.380% | -2.419% | -10.425% | 41.667% | 12.957% | 29.969% | -1.653% |
Comments
Repligen (RGEN) had its price target lowered by UBS Group AG from $200.00 to $195.00. They now have a "buy" rating on the stock.
Show more
Ratings data for RGEN provided by MarketBeat
Repligen (RGEN) had its price target lowered by Barclays PLC from $200.00 to $175.00. They now have an "overweight" rating on the stock.
Show more
Ratings data for RGEN provided by MarketBeat
Repligen (RGEN) had its price target lowered by Wells Fargo & Company from $190.00 to $180.00. They now have an "overweight" rating on the stock.
Show more
Ratings data for RGEN provided by MarketBeat